课题基金 / 基金详情

项目摘要

项目成果

Melissa Lambeth Kemp的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Adoptive transfer of T cells is a promising clinical cancer therapy that relies on enhancing the adaptive immune response to target tumor cells in vivo. Widespread application of this therapy, however, has been hindered by the necessary expansion of large populations of T cells for each patient (often selected for tumor antigen specificity) and loss of functionality of the T cells post-transfer. Our long-term objective is to understand how T cell activation is dampened in vivo by the tumor milieu and to be able to evaluate the responsiveness ex vivo-expanded T cells accurately for cancer therapy. Microfluidic chips are ideal for high-throughput parallel experimentation and automation. In addition, microfluidics also provides the relevant length scales (~microns) and unique physical phenomena (e.g. laminar flow) to handle cells. The type of multiplex data that we can obtain from this technology will enable quantitative modeling of T cell activation and better understanding and characterization of anergy. The objective of this R21 project is to engineer a multiplex microfluidic assay to quantify T cell activation on a small population of cells with high temporal resolution. The hypothesis is that capturing the early dynamics of T cell activation of ex vivo expanded clones would improve upon current measures of T cell functionality. The first component of this project is to develop the high-throughput microfluidic system for multiple time-point stimulation and lysis of cells; in parallel, we are to develop biochemical assays to characterize the performance of the system and the cell state. The second component is to perform in vitro characterization of ex vivo expanded T cells for distinguishing anergic versus responsive behavior. The approach is innovative because the technology developed here dramatically increases the capabilities and throughput of existing assays in evaluating T cells for adoptive transfer. Furthermore, this work proposes and tests a new paradigm in T cell evaluation using multiplex quantitative means. The proposed research is significant because it is expected to expand the toolbox of cancer therapy and possibly other related quantitative biosciences and medical technologies.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1039/b810896j
发表时间: 2009-02-21
期刊: Lab on a chip
影响因子: 6.1
作者: [Hirsch AM, Rivet CA, Zhang B, Kemp ML, Lu H]
通讯作者: Lu H
Predicting cytotoxic T-cell age from multivariate analysis of static and dynamic biomarkers.
通过静态和动态生物标志物的多变量分析预测细胞毒性 T 细胞年龄。
DOI: 10.1074/mcp.m110.003921
发表时间: 2011
期刊: Molecular & cellular proteomics : MCP
影响因子: --
作者: [Rivet,CatherineA, Hill,AbbyS, Lu,Hang, Kemp,MelissaL]
通讯作者: Kemp,MelissaL
DOI: 10.1039/c7lc00763a
发表时间: 2017-10-25
期刊: Lab on a chip
影响因子: 6.1
作者: [Jackson-Holmes EL, McDevitt TC, Lu H]
通讯作者: Lu H
Spatiotemporal control of reactive oxygen species in T cells
  • 批准号:
    8316150
  • 项目类别:
  • 资助金额:
    $36.47万
  • 财政年份:
    2011
  • 负责人:
    Melissa Lambeth Kemp
  • 依托单位:
Spatiotemporal control of reactive oxygen species in T cells
  • 批准号:
    8040568
  • 项目类别:
  • 资助金额:
    $36.21万
  • 财政年份:
    2011
  • 负责人:
    Melissa Lambeth Kemp
  • 依托单位:
Spatiotemporal control of reactive oxygen species in T cells
  • 批准号:
    8704863
  • 项目类别:
  • 资助金额:
    $36.74万
  • 财政年份:
    2011
  • 负责人:
    Melissa Lambeth Kemp
  • 依托单位:
Spatiotemporal control of reactive oxygen species in T cells
  • 批准号:
    8512651
  • 项目类别:
  • 资助金额:
    $34.28万
  • 财政年份:
    2011
  • 负责人:
    Melissa Lambeth Kemp
  • 依托单位:
海外基金